ImmunoGen, Inc. (IMGN) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Waltham, MA, United States. El CEO actual es Mark Joseph Enyedy.
IMGN tiene fecha de IPO 1989-11-17, 277 empleados a tiempo completo, cotiza en el NASDAQ Global Select, una capitalización de mercado de $8.73B.
ImmunoGen, Inc. is a clinical-stage biotechnology company focused on developing antibody-drug conjugate (ADC) therapies for cancer treatment. The company's lead candidate, mirvetuximab soravtansine, targets folate-receptor alpha and is in Phase III trials for platinum-resistant ovarian cancer, while Pivekimab sunirine, a CD123-targeting ADC, is in Phase II development for acute myeloid leukemia and related blood cancers. ImmunoGen maintains a robust pipeline of preclinical programs and strategic collaborations with major pharmaceutical companies including Roche, Amgen, Bayer, Eli Lilly, Novartis, and others. Founded in 1980 and headquartered in Waltham, Massachusetts, the company leverages proprietary ADC technology to advance novel cancer therapies.
